Immuneering Completes Dose Escalation In IMM-1-104 Phase 1 Clinical Trial For RAS-Mutant, Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Immuneering has completed dose escalation in its IMM-1-104 Phase 1 clinical trial for RAS-mutant, advanced solid tumors. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of the drug.
June 05, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuneering has completed dose escalation in its IMM-1-104 Phase 1 clinical trial, potentially bringing the company closer to developing a treatment for RAS-mutant, advanced solid tumors.
The completion of dose escalation in the IMM-1-104 Phase 1 clinical trial is a positive development for Immuneering. This milestone brings the company closer to potentially developing a treatment for RAS-mutant, advanced solid tumors, which could have a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100